RESEARCH ANTIBODIES MARKET ANALYSIS

Research Antibodies Market Size and Trends

Global research antibodies market is estimated to be valued at USD 11.91 Bn in 2024 and is expected to reach USD 18.60 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.

To learn more about this report, request sample copy

Global Research Antibodies Market Trend-

There are several variables that propel the market for research antibodies. Proteomics and genomics research is on the rise, as are research academies and industrial partnerships, as well as increased R&D spending. Research antibodies play a crucial role in biopharmaceutical and pharmaceutical research since they are necessary for understanding the origins of diseases and for examining biological processes. Thus, the market is expanding due to expanding research on stem cells and neurobiology worldwide, as well as product advancements and company collaboration.

Increasing research and development activities

Global research antibodies market growth is driven by increased research and development activities. Global research antibodies market growth is driven by increased investment in research and development, heightened collaboration between research institutions and industries, and surge in proteomics and genomics studies. Research antibodies are integral to biopharmaceutical and pharmaceutical research, facilitating the exploration of biological processes and the understanding of disease mechanisms. With expanding stem cell and neurobiology research worldwide, coupled with continuous product innovations and industry collaborations, the market is witnessing significant growth. For instance, in March 2022, according to the study published by Journal eLife, researchers from the University of Washington, the Max Planck Institute for Dynamics and Self-Organization, and the University of Cologne focused on broadly neutralizing antibodies (bNAbs). The research highlighted the potential of bNAbs in treating HIV while mitigating the risk of viral transmission. The study underscores the importance of computational approaches in selecting optimal combinations of bNAbs based on viral genetics to enhance HIV treatment efficacy and prevent viral escape.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Get instant access to report

Growing Investments & Increasing product launches

Increased investments from both public and private sectors in life science R&D can drive the research antibodies market growth. This is fueled by the recognition of the importance of basic research in fields like immunology, cancer biology, genetics, and neuroscience. The development of novel antibody-based therapeutics and diagnostics is attracting substantial capital, leading to growing demand for research antibodies in academic and industry labs. This trend is supported by sophisticated core facilities in leading research institutions, indicating sustained growth potential for the market. Product approvals by industry participants can drive the research antibody market growth during the forecast period. Tepezza (TM) (teprotumumab-trbw), a therapeutic monoclonal antibody for the treatment of thyroid eye disease (TED), was approved by the U.S. Food and Drug Administration on January 21, 2020. Horizon Therapeutics plc is a biopharmaceutical company that focuses on researching, developing, and commercializing medicines, and it had developed Tepezza (TM) (teprotumumab-trbw). TED is an unusual autoimmune disorder that is severe, progressive, and potentially blinding. It is characterized by pain, inflammation, deformity of the face, diplopia (double vision), proptosis (eye bulging), and blurred vision. The FDA (Food and Drug Administration) in the U.S. had approved Tepezza as the sole drug for TED patients.

Key Takeaways from Analyst:

Global research antibodies market is expected to witness steady growth over the next five years. Rising investments by both private and public players in R&D activities can boost demand for research antibodies. Furthermore, increasing prevalence of cancer and other chronic diseases is prompting pharmaceutical companies to focus on developing novel therapeutics, thus, propelling the need for research antibodies in drug discovery processes.

However, stringent regulations surrounding the clinical uses of antibodies may hinder the market growth. High cost involved in the development of antibodies can pose challenge for small research institutions and startups.

North America currently dominates the research antibodies market and is expected to maintain its lead during the forecast period due to the robust biopharmaceutical industry and mounting healthcare expenditures in the region. Meanwhile, Asia Pacific exhibits high growth potential fueled by expanding R&D facilities, growing biotech hubs in China and India, and improving healthcare infrastructure.

On the products front, monoclonal antibodies are likely to witness the highest demand owing to their wide applications across various research areas. In terms of application, western blotting, flow cytometry, immunohistochemistry, and immunofluorescence are some dominating techniques fueling the need for research-grade antibodies.

Market Challenges: Stringent regulations for antibody production

Stringent regulations surrounding the production and storage of antibodies increases costs. Maintaining antibody effectiveness over longer shelf lives is difficult. The development of new antibody technologies requires large investments in R&D. Intellectual property issues around antibody development discourages innovation. Educating researchers on proper antibody selection and application takes significant resources. The market is also constrained by the limited number of validation studies supporting new antibody types.

Market Opportunities: Demand for antibodies in drug discovery & research

There has been huge demand for antibodies in drug discovery and disease research. Customized antibody services allow for targeting new disease areas. Outsourcing antibody manufacturing to specialized companies can boost efficiency. Adopting single-use technologies assists in avoiding contamination issues. Collaboration between industry and academia helps identify promising new applications.

Discover high revenue pocket segments and roadmap to it: Get instant access to report

Insights, By Product Type: Growing Demand for Target-Specific Detection Drives Primary Antibodies Segment Growth

In terms of product type, primary antibodies segment is estimated to contribute the highest market share of 45.1% in 2024, owing to its widespread applications across various research areas. Primary antibodies are highly specific, and are used to detect target antigens or proteins in samples. This makes them ideal for various detection and localization techniques in cell and tissue imaging. Their ability to bind uniquely to epitopes makes them valuable tools in research applications exploring protein expression and function. Western blotting is one of the most commonly used techniques that relies heavily on high quality primary antibodies for reliable results. Other techniques like flow cytometry, immunohistochemistry and ELISA also utilize primary antibodies as the critical detection agent. The target-specific binding property of primary antibodies has propelled their adoption across diverse fields like cancer research, neuroscience, immunology and many more. Researchers prefer primary antibodies due to the confidence these provide in accurately detecting the protein of interest. This widespread applicability and reliability have established primary antibodies as the largest segment in the overall research antibodies market.

Insights, By Delivery Model:  Monoclonal Antibodies Dominate Due to Consistency and Specificity

In terms of form, monoclonal antibodies segment is estimated to contribute the highest market share of 60.12% in 2024 due to their consistent performance and specificity. Monoclonal antibodies are produced by identical immune cells that are all clones of a unique parent cell. This cloning process allows mass production of antibodies that bind exclusively to the same epitope. The consistency in specificity and affinity offered by monoclonal antibodies makes them the antibody of choice for many critical research applications. These play a key role in techniques like immunoblotting, ELISA and immunohistochemistry by helping deliver reproducible, quantifiable results. Their defined specificity has made them an indispensable tool in research exploring protein expression and functions. Moreover, monoclonal antibodies can now be produced against a wide variety of target molecules with standardized procedures, fueling their widespread adoption. The uniformity in structure and specificity of monoclonal antibodies has positioned them as the dominant antibody type preferred by researchers.

Insights, By Application- Advancements in Western Blot Drive Adoption across Proteomics

In terms of application, western blotting segment is estimated to contribute the highest market share of 25.14% in 2024, owing to continuous methodological advancements. Western blotting is a commonly employed analytical technique that is used to detect specific proteins in a given sample of tissue homogenate or extract. It relies on antibody-based detection of proteins separated through gel electrophoresis. Advancements in gel electrophoresis, membrane transfer techniques and antibody specificity have significantly improved western blotting performance metrics like speed, sensitivity and accuracy. This has enabled western blotting to evolve into a robust tool for research areas like proteomics. Increased sensitivity allows reliable protein detection even from minute samples. Automated systems have sped up western blot workflows. Researchers have embraced western blotting for exploratory analyses of protein expression changes. Its ability to detect post-translational modifications has expanded its applications. With persistent developments enhancing western blotting's versatility, it will continue to drive significant antibody demand across varied research domains examining protein functions.

Regional Insights

To learn more about this report, request sample copy

North America has remained the largest and most dominant regional market for research antibodies over the past decade with estimated share of 38.2% in 2024 due to multiple factors supporting the industry's growth in the region. The presence of major pharmaceutical players and contract research organizations has driven significant antibody-based research and development activities across the U.S. and Canada. The region is a leader in biotechnology with a strong emphasis on medical innovation and new drug development. This has translated into sizable investments and funds allotted for antibody research by both public and private organizations.

The U.S. in particular hosts a large pool of skilled researchers and scientists supported by top-tier academic institutions. Several state-of-the-art core facilities and research laboratories possessing antibody production and validation capabilities have further strengthened North America's position. Collaborations between industry and academia have also led to rapid commercialization of novel antibody therapeutics and diagnostics. Stringent regulatory standards ensure high product quality and safety, maintaining the region's reputation as a reliable and preferred sourcing hub for research antibodies.

Market Report Scope

Research Antibodies Industry News

• On May 30, 2024, Scientists from Texas Biomedical Research Institute, the University of Alabama at Birmingham, and Columbia University developed a human monoclonal antibody effective against multiple strains of SARS-CoV-2. Led by Dr. Luis Martinez-Sobrido, the research offers promise for a universal antibody, as it demonstrated efficacy against the original SARS-CoV-2, Omicron, and SARS-CoV. This breakthrough, published on BioRXiv, suggests potential for future strain defense when combined with other antibodies.
• In February 2022, Abcam, Biotechnology company, announced its collaboration with Twist Bioscience, a leading provider of synthetic DNA, aiming to enhance antibody discovery for diagnostic and research applications
• In February 2022, Merck Millipore a life science company announced its acquisition of Exelead for approximately US$ 780 million. This acquisition enables Merck's Life Science business division to offer end-to-end CDMO services across the mRNA value chain to its customers.
• In November 2021, Nautilus Biotechnology a development stage life sciences company announced a strategic agreement with Abcam to accelerate research and development of the Proteome. This agreement grants Nautilus Biotechnology's customers access to Abcam's antibody development technology and expertise.

*Definition: The research antibodies market consists of companies that manufacture and sell antibodies for research purposes in biotechnology and pharmaceutical industries. Researchers use antibodies in various laboratory techniques like ELISA, Western blot, immunofluorescence and immunohistochemistry to study the presence, location and concentration of antigens in biological samples which helps gain insights into causes of diseases and develop diagnostics and therapeutics. The key players in this market focus on developing monoclonal and polyclonal antibodies against a wide range of antigen targets.

Market Segmentation

•  Product Type Insights (Revenue, USD BN, 2019 - 2031)
  • Primary Antibodies
  • Secondary Antibodies
  • Reagents
  • Consumables
• Form Insights (Revenue, USD BN, 2019 - 2031)
  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Recombinant Antibodies
• Application Insights (Revenue, USD BN, 2019 - 2031)
  • Western Blotting
  • ELISA
  • Flow Cytometry
  • Immunocytochemistry (ICC)/ Immunofluorescence (IF)
  • Immunohistochemistry (IHC)
  • Others (Immunoprecipitation, Multiplex Immunosorbent Assay and etc.)
•  End User Insights (Revenue, USD BN, 2019 - 2031)
  • Academic & Research Institutes
  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
• Regional Insights (Revenue, USD BN, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa     
• Key Players Insights
• • Thermo Fisher Scientific, Inc.
  • Merck KGaA (including Sigma-Aldrich)
  • Abcam plc
  • Cell Signaling Technology, Inc.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Lonza Group AG
  • GenScript Biotech Corporation
  • BioLegend, Inc.
  • Bio-Techne Corporation
  • F. Hoffmann-La Roche Ltd
  • Santa Cruz Biotechnology, Inc.
  • BD Biosciences (Becton, Dickinson and Company)
  • PerkinElmer, Inc.
  • Active Motif
  • QIAGEN N.V.
  • OriGene Technologies, Inc.
  • Jackson ImmunoResearch Laboratories, Inc.
  •    R&D Systems (part of Bio-Teachne Corporation)
  • Proteintech Group, Inc.